Cargando…

Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience

Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrucci, Silvia, Casazza, Giovanni, Angileri, Luisa, Tavecchio, Simona, Germiniasi, Francesca, Berti, Emilio, Marzano, Angelo Valerio, Genovese, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141229/
https://www.ncbi.nlm.nih.gov/pubmed/32183179
http://dx.doi.org/10.3390/jcm9030791
_version_ 1783519151303688192
author Ferrucci, Silvia
Casazza, Giovanni
Angileri, Luisa
Tavecchio, Simona
Germiniasi, Francesca
Berti, Emilio
Marzano, Angelo Valerio
Genovese, Giovanni
author_facet Ferrucci, Silvia
Casazza, Giovanni
Angileri, Luisa
Tavecchio, Simona
Germiniasi, Francesca
Berti, Emilio
Marzano, Angelo Valerio
Genovese, Giovanni
author_sort Ferrucci, Silvia
collection PubMed
description Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16, disease severity was assessed through the Eczema Area and Severity Index (EASI) and quality of life through the Dermatology Life Quality Index (DLQI) questionnaire, Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), Peak Pruritus Numerical Rating Scale (NRS-itch), and VAS-sleep. Response to dupilumab was defined as an improvement of ≥75% in EASI from baseline (EASI75). At multivariate analysis, AD onset before 18 years [OR, 2.9; 95% CI, 1.2–7.2; p = 0.0207] and absence of hypereosinophilia [OR, 2.24; 95% CI, 1.03–4.86; p = 0.0412] were identified as significant predictive parameters for response to dupilumab in terms of EASI75 at week 4 but not at week 16. Significant reductions in EASI, DLQI, POEM, HADS, NRS-itch, and VAS-sleep were found between week 4 versus baseline (p < 0.0001 for all) and week 16 versus baseline (p < 0.0001 for all). Early AD onset and absence of hypereosinophilia may be suggested as predictive markers of early response to dupilumab. We confirmed the efficacy and safety of this agent along with the improvement of life quality in severe AD patients.
format Online
Article
Text
id pubmed-7141229
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71412292020-04-10 Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience Ferrucci, Silvia Casazza, Giovanni Angileri, Luisa Tavecchio, Simona Germiniasi, Francesca Berti, Emilio Marzano, Angelo Valerio Genovese, Giovanni J Clin Med Article Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16, disease severity was assessed through the Eczema Area and Severity Index (EASI) and quality of life through the Dermatology Life Quality Index (DLQI) questionnaire, Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), Peak Pruritus Numerical Rating Scale (NRS-itch), and VAS-sleep. Response to dupilumab was defined as an improvement of ≥75% in EASI from baseline (EASI75). At multivariate analysis, AD onset before 18 years [OR, 2.9; 95% CI, 1.2–7.2; p = 0.0207] and absence of hypereosinophilia [OR, 2.24; 95% CI, 1.03–4.86; p = 0.0412] were identified as significant predictive parameters for response to dupilumab in terms of EASI75 at week 4 but not at week 16. Significant reductions in EASI, DLQI, POEM, HADS, NRS-itch, and VAS-sleep were found between week 4 versus baseline (p < 0.0001 for all) and week 16 versus baseline (p < 0.0001 for all). Early AD onset and absence of hypereosinophilia may be suggested as predictive markers of early response to dupilumab. We confirmed the efficacy and safety of this agent along with the improvement of life quality in severe AD patients. MDPI 2020-03-13 /pmc/articles/PMC7141229/ /pubmed/32183179 http://dx.doi.org/10.3390/jcm9030791 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ferrucci, Silvia
Casazza, Giovanni
Angileri, Luisa
Tavecchio, Simona
Germiniasi, Francesca
Berti, Emilio
Marzano, Angelo Valerio
Genovese, Giovanni
Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
title Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
title_full Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
title_fullStr Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
title_full_unstemmed Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
title_short Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
title_sort clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141229/
https://www.ncbi.nlm.nih.gov/pubmed/32183179
http://dx.doi.org/10.3390/jcm9030791
work_keys_str_mv AT ferruccisilvia clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience
AT casazzagiovanni clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience
AT angileriluisa clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience
AT tavecchiosimona clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience
AT germiniasifrancesca clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience
AT bertiemilio clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience
AT marzanoangelovalerio clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience
AT genovesegiovanni clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience